NCT05366660

Brief Summary

Cardiac Implantable Electronic Devices (CIEDs) such as pacemakers and implantable cardioverter defibrillators, need to be regularly interrogated and reprogrammed to ensure proper functioning. While remote monitoring allows for partial interrogation at a remote location, full interrogation and changing the CIED parameters is only possible when the patient visits a cardiologist capable of performing device programming. This can be challenging for patients and may cause unnecessary delays, particularly in settings of limited resources, enforced physical distancing, and quarantines. We aim to investigate the efficacy and safety of remote programming.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 8, 2021

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 4, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 4, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 5, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 9, 2022

Completed
Last Updated

June 17, 2025

Status Verified

June 1, 2025

Enrollment Period

10 months

First QC Date

May 5, 2022

Last Update Submit

June 12, 2025

Conditions

Keywords

Implantable cardioverter defibrillatorICDPacemakerTelemedicineRemote monitoringCardiac implantable electronical device

Outcome Measures

Primary Outcomes (1)

  • Successful remote interrogation and programming of CIED

    Success rate of remote interrogation and programming of CIED

    18 months

Secondary Outcomes (4)

  • To assess the user-friendliness of the system (1)

    18 months

  • To assess the user-friendliness of the system (2)

    18 months

  • To assess the user-friendliness of the system (3)

    18 months

  • To assess the user-friendliness of the system (4)

    18 months

Study Arms (1)

CIED's interrogation/programming

EXPERIMENTAL

All the patients will be included in this single arm to interrogate/programm their CIED

Other: Interrogation/programming

Interventions

As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side). Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system. Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient. The patient will first be connected to the programmer as during a conventional follow-up. The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator. This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.

CIED's interrogation/programming

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient of both sexes over the age of 18
  • Patients implanted with a cardiac pacemaker or an automatic defibrillator and an indication for device check-up (interrogation ± programming) which may be periodic as part of their follow-up, postoperative, following a remote monitoring alert, pre/post MRI or following symptoms.
  • Person beneficiary of social security insurance.
  • Women of procreating age with effective contraception

You may not qualify if:

  • Patients younger than 18 years old
  • Patients who are incapable to understand the study design or to give informed consent.
  • Pregnant or breastfeeding women
  • Persons placed under judicial protection, curatorship, tutorship.
  • Subject deprived of liberty on judicial or administrative decision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bordeaux University Hospital

Pessac, France, 33604, France

Location

Study Officials

  • Sylvain MD Ploux

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Model Details: Multicenter feasibility study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 5, 2022

First Posted

May 9, 2022

Study Start

June 8, 2021

Primary Completion

April 4, 2022

Study Completion

April 4, 2022

Last Updated

June 17, 2025

Record last verified: 2025-06

Locations